700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
To determine the incidence of hepatotoxicity in HIV sero positive and to investigate whether antiretroviral drugs could predispose HIV sero positive patients on antiretroviral drugs to hepatotoxicity.HIV patients were on antiretroviral drugs (triviro-LNS-Lamivudine, Nevirapine and Starvudine) 1-2 pills daily depending on the CD4 count. Moreso, have been on the drug for the duration of 2- 3 years. Blood samples were collected for the determination of clinical chemistry parameters such as liver enzymes (Les)-Lactate Dehydrogenase (LDH), Aspartate and Alanine Transaminases (AST and ALT) and Albumin (ALB). Sixty subjects were randomly selected and placed in three groups comprising 20 HIV infected patients who are not receiving antiretroviral drugs and group two twenty receiving antiretroviral drugs. Another twenty healthy non infected patients made up group 3 and these groups served as control, the patients are within Aba metro. The patients’ blood was collected and the serum separated. It was subsequently used for the analysis. All analysis was based on colorimetric method.The results obtained were subjected to statistical analysis using one-way analysis of variance. The result of the study showed that those patients on antiretroviral drugs had remarkable increase in LDH and AST levels compared to those not on the antiretroviral drugs and HIV negative patients (control (U/L) LDH 184.00± 5.75 VS 546 ± 25.60. AST control (U/L) 24.7.± 4.6 VS 67.95 ± 10.5. P<0.05).
To read the full article Peer-reviewed Article PDF
Author(s): Igboh, N. M; Nnamah, N. K; Onwubiko, D; Chigbu, L. N; Agomuo, E. N3; Onyesom,C. A, Maduagwun, C. A; Iheanacho, K, M. E6; Emuchey, C. I.